top of page

Five companies join the Alliance for Biosecurity

The new members add to the Alliance’s vast scope of expertise behind the same singular focus of strong, consistent national health security

WASHINGTON, DC – Five U.S. companies announced they have joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies – along with laboratory and academic partners – that promotes a strong public-private partnership in order to ensure the medical countermeasures that protect public health are effective and readily available.


The Alliance’s newest member companies – Opiant, Roche Diagnostics, SCYNEXIS, Tonix, and Venatorx – represent a wide array of expertise within the private industry that supports national health security and bring the coalition’s membership to 18 total companies and organizations.


“We welcome the newest members of the Alliance who have joined us to provide varying perspectives and contribute to our expanding scope. Together, we are uniquely equipped to help guide and further develop public-private partnerships that protect the American people from chemical, biological, radiological or nuclear threats,” said Alliance for Biosecurity Co-Chair Brent MacGregor.


The Alliance for Biosecurity supports national health security by advocating for public policies and funding to support the rapid development, production, stockpiling, and distribution of critically needed medical countermeasures that are used to prevent and respond to a variety of threats.


"The threats that would call our products into use are considered to have catastrophic potential,” said Alliance Co-Chair Chris Frech. “In the interest of preparedness and national security, industry and government work together to ensure that the necessary countermeasures are developed, manufactured, and delivered to the strategic national stockpile or that the infrastructure exists to respond to such emergencies. Because the U.S. government creates the demand for these products by authorizing funding for procurement and development, it benefits both sides to have clarity of requirements so industry can adequately meet the government's needs."


“For the Alliance to accurately represent industry in these situations, it is important that we have well-rounded knowledge to bring to these public-private partnerships. Our new members help give us a vast scope of expertise behind the same singular focus: strong and resilient national health security.”


Meet the newest member companies of the Alliance for Biosecurity:


Opiant is a pharmaceutical company headquartered in Santa Monica with a mission to create best-in-class medicines for the treatment of addictions and drug overdose.

Roche Diagnostics provides in vitro diagnostics solutions to help healthcare providers make faster, more confident diagnoses and therapy decisions to improve people’s health.


SCYNEXIS is a biotech company developing a novel class of systemic antifungals to combat multiple serious and life-threatening infections, including those caused by Candida auris, an emerging fungus classified as an “Urgent Threat” by the CDC.


Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing new treatments for psychiatric, pain and addiction conditions, as well as biological products to improve biodefense through potential medical countermeasures.


Venatorx Pharmaceuticals is focused on the discovery and development of novel anti-infectives to treat multi-drug resistant bacterial infections and hard-to-treat viral infections.

bottom of page